Our vision

Reperia is derived from the Latin word ‘reperio’ meaning discovery and used by the ancient roman scientists to describe their work on identifying new ways of treating diseases.

BioReperia is dedicated to providing unique services within toxicology and anti-cancer drug-discovery allowing our customers to more efficiently select and move the best new drug candidates rapidly through pre-clinical development.

The team

BioReperia is located at Linköping University. Our researchers have more than 10 years experience developing and using zebrafish models for medical research including toxicology and tumor biology. Our models are today widely used in both academic and industrial research and drug development projects around the globe.

Contact

Lasse Jensen, PhD
Co-founder
lasse.jensen@bioreperia.com
Mobile:+46 70 998 20 96

Anna Fahlgren, PhD
Co-founder
anna.fahlgren@bioreperia.com
Mobile: +46 72 323 94 74

Shortening time to drug discovery

BioReperia
ACCELERATE DRUG DISCOVERY

Kungsgatan 24 • SE-582 18 Linköping • Sweden
www.bioreperia.com

BioReperia
ACCELERATE DRUG DISCOVERY

Zebrafish models

Zebrafish embryos reveal toxic or therapeutic effects of new drug candidates in a matter of days. It is the only animal system amenable for high throughput drug screening.

Our methods are cheaper, faster and more accurate than other animal studies, and more biomedically relevant than cell culture experiments.

Many drug candidates are eventually dismissed due to efficacy or toxicity issues. Do as thousands of other bio-tech companies. Save time and money by allowing drugs with no future to fail early and fast through the use of zebrafish!

Toxicology

Drug toxicities are not accurately determined from cell culture experiments. Zebrafish embryos are widely-used, versatile toxicity reporters. Both general and specific toxicities in zebrafish correlate very well with toxicities
in mice or humans.

Determination of LD50 (50% lethality dose), MTD (maximally tolerated dose), NOAED (no observed adverse effects dose) and pharmacodynamics in vivo are determined in days.

Using zebrafish you will get all relevant toxicity data for less than 10% of the cost of other animal models, while maintaining biomedical relevance!

Oncology

We are unique in offering zebrafish tumor xenograft models based on implanting human or mouse tumor cells into zebrafish embryos, providing the fastest, and most reliable method to evaluate anti-tumor drug effects on the market.

Tumor growth/regression and metastasis rates are established during three days. IC50 values and therapeutic windows are determined comparing anti-tumor efficacy with toxicity in the same animal.

Zebrafish tumor models save 90% of your time, money and drug compared to mouse models, and include more accurate and pathophysiologically relevant insights including data on metastasis.



200 eggs / week



Toxicity

Oncology



– Drug



+ Drug

Whole embryos



Local metastasis

Distal metastatis



GREEN: Blood vessels

RED: Tumor cells

Zebrafish embryos, absorb drugs passively from the water and are small enough for the 96-well plate format.

Morphologic changes in the embryos are used to predict whether a drug exhibit general or specific toxicity (i.e. to an organ such as the head).

Tumor growth and metastasis is quantified by comparing the growth/regression rate and the numbers of disseminating cells between the groups.